Connect with us

CBD

The FDA Is Quietly Targeting CBD In 2022

Published

on


The Food and Drug Administration (FDA) has consistently taken the position that cannabidiol derived from hemp (CBD) cannot be marketed or sold as a dietary supplement or food. The FDA’s position is based on the fact that CBD has been approved for use in a pharmaceutical drug and therefore cannot legally be sold in any ingestible form.

In addition, if a CBD company makes any health or wellness claims (e.g., CBD can help you relax, CBD cures back pain) then the FDA will consider the product an unauthorized drug.

The FDA has enforced this position against companies selling CBD by issuing Warning Letters, which, as the name suggests, warns companies regarding the improper sale of adulterated and misbranded foods. Despite the consistency from the FDA, there has been a recent uptick from the agency in sending out Warning Letters to CBD companies.

RELATED: The FDA Sets Targets On Delta-8

FDA warning letters chart

*note: one letter was sent in 2022 to a company selling delta-8 and is not reflected in this graph.

As you can see, the Warning Letters spiked in 2019, which coincides with the passage of the 2018 Farm Bill in December 2018. With the rise of Covid, the FDA was preoccupied with the pandemic and the amount of Warning Letters decreased significantly. However, it appears that the FDA is again setting its sights on CBD, with 13 Warning Letters going out in 2022. I would expect that number to increase because the year is not yet complete.

Warning Letters are a fairly minor enforcement action. However, the FDA also has the authority to levy fines and even refer cases to the Department of Justice. A Warning Letter can also lead to more severe actions from the FDA, as well as harm a company’s reputation and spook investors.

RELATED: How Would The Cannabis Administration And Opportunity Act Work?

Because of this uptick in Warning Letters, it’s a good time to reevaluate how to mitigate risks of selling CBD. This requires avoiding any direct or indirect claim that CBD has any health or wellness benefits. Direct claims are along the lines of “CBD cures insomnia” or “CBD can treat anxiety.” Indirect claims can be referencing a study regarding CBD, posting customer reviews indicating that CBD has some medical benefit, or implying in any way that CBD does in fact have some positive health or wellness impact.

If you are unsure how to mitigate the risks associated with CBD products, feel free to reach out to our regulatory attorneys for more information.

Daniel Shortt is a corporate and regulatory attorney based in Seattle, Washington who works extensively with entrepreneurs in the cannabis industry. You can contact him at info@gl-lg.com or (206) 430-1336. This article originally appeared on Green Light Law Group and has been reposted with permission. 



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.

CBD

BOGO on all CBD+THC products from Vena

Published

on

By


Vena logo


Presented ByVena

Vena is here to empower you to experience a more complete life with their CBD+THC gummies, supplements, and skincare products. To help you explore what Vena’s approach to sustainable vitality could do for you, they are offering a BOGO sale on everything sitewide. Just use code LEAFLY at checkout!

That’s right: buy one, get one on Vena’s wide range of CBD and CBD+THC offerings. With a deal like that, it’s never been easier to discover CBD-powered wellness.

Women-led Vena is dedicated to supporting a balanced lifestyle for their customers. This transparent company offers quality, safety-tested products to help you on your journey to manifest your best self. 


Buy one, get one on all products sitewide. Add two items to cart and get the equal or lesser value product for free with code LEAFLY at checkout. Limit one (1) code per order. Excludes subscriptions.

Vena Logo



Source link

Continue Reading

CBD

Medical cannabis for doggies, kitties is fully legalized in California

Published

on

By


Newly enacted bill in California allows veterinarians to “recommend” medical cannabis products for their furry patients. Before, vets could only “discuss” such products with their patients’ owners, leading many vets to avoid the topic rather than risk losing their license.

https://www.leafly.com/news/politics/mmj-pet-legalization-california



Source link

Continue Reading

CBD

Free THC+CBD from Medterra | Leafly

Published

on

By


Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly’s Terms of Service and Privacy Policy. Offer valid for new Leafly subscribers. Available to US residents only, valid only where legal.



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media